Goldman predicts setbacks for Genzyme

Goldman Sachs added Genzyme to its Americas conviction sell list, saying that manufacturing setbacks at one of its plants may impair long-term growth at the company, and a near-term shortage of its drug Cerezyme may be more severe than expected. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.